Epidermal growth factor receptor (EGFR) inhibitors were among the first type of targeted
agents discovered in cancer and currently constitute the standard of care for a wide range of …

Epidermal growth factor receptor (EGFR), the receptor for members of the epidermal growth
factor family, regulates cell proliferation and signal transduction; moreover, EGFR is related …

Epidermal growth factor receptor (EGFR), a receptor tyrosine kinase, is activated by ligand
binding, overexpression, or mutation. It is well known for its tyrosine kinase-dependent …

Background: Agents targeting the epidermal growth factor (EGFR)-mediated signaling
pathway are used in the treatment of various solid tumors, including lung, breast, pancreatic …

EGFR is a tyrosine kinase that participates in the regulation of cellular homeostasis.
Following ligand binding, EGFR stimulates downstream cell signaling cascades that …

Inhibition of the epidermal growth factor receptor as a target for cancer chemotherapy has
proven to be an effective treatment in both preclinical and clinical settings. Recent work has …

The epidermal growth factor receptor (EGFR) has been widely used as a target for novel
anticancer agents, such as blocking antibodies and small molecular weight tyrosine kinase …

In recent years, the epidermal growth factor receptor (EGFR) has been recognized as a
central player and regulator of cancer cell proliferation, apoptosis and angiogenesis and …

Epidermal growth factor receptor (EGFR) is a validated target in different human
malignancies. EGFR tyrosine kinase inhibitors (TKIs) are known to contribute considerably …

The epidermal growth factor receptor (EGFR) is overexpressed in many solid tumours.
Targeting EGFR is emerging as a potential strategy to incorporate into cancer treatment …